CAMBRIDGE, Mass.--(BUSINESS WIRE)--DART Therapeutics, Inc., announced today that it has changed its name to Akashi Therapeutics to reflect its progress in developing a pipeline of product candidates to improve the lives of children with Duchenne muscular dystrophy (DMD). The new company name is derived from the Akashi-Kaikyo bridge in Japan which has the longest central span of any suspension bridge in the world. The name symbolizes how Akashi Therapeutics was created to save children’s lives by rapidly bridging the gap between promising science and effective treatments for Duchenne. Akashi Therapeutics combines the operations of DART and its subsidiary Halo Therapeutics, LLC, into a single entity. Simultaneous with the name change, the company has launched a new corporate website and URL: www.akashirx.com
Help employers find you! Check out all the jobs and post your resume.
